Dr. Byoung Chul Cho presented elisrasib (D3S-001), next gen KRAS G12C inhibitor in NSCLC at #AACR26. Images not posted by request. In 84 ...

Back to meeting Original

Back to meeting

Stephen V Liu, MD· @StephenVLiu · X·2026-04-20 22:25· 2026-04-20Score60

elisrasib

Reading

KRAS / RAS targeting: from platform to Phase 3

Chinese groups are not short of G12C molecules (elisrasib’s floor numbers are strong).

Body

Dr. Byoung Chul Cho presented elisrasib (D3S-001), next gen KRAS G12C inhibitor in NSCLC at #AACR26. Images not posted by request. In 84 pts with no prior G12C inhibitor, RR 59.5%, DCR 98.8%, PFS 9.4m. In pts with prior G12Ci, RR 32.3%, DCR 83.9% DOR 15.6, PFS 8.1m. ctDNA

Heat 0 · 0 likes · 0 replies · 0 reposts

Conference abstracts

CT303NCT05410145matched by 药名 cetuximab

Safety and efficacy of Elisrasib (D3S-001), a next generation GDP-bound KRAS G12C inhibitor, as monotherapy or combination therapy with cetuximab in previously treated metastatic CRC and PDAC: Results from a phase 1/2 study

Kanwal Pratap Raghav, Jun Zhang, Myung-Ah Lee, Jingdong Zhang, John Park, Yanqiao Zhang, Susana Rosello Keranen, Byoung Chul Cho, Herbert Ho Fung Loong, Cheng Chen, Huan Li, Shaonan Wang, Yandong Shen, Zifei Fan, Qian Chen, Hui Wang, Jing Zhang, George Zhi Jian Chen, Jayesh Desai, Antoine Hollebecque

Read the abstract →

Source: Stephen V Liu, MD · x.com